JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70

Benzinga · 1d ago
JP Morgan analyst Joyce Zhou initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Overweight rating and announces Price Target of $70.